GSK in talks to buy cancer biotech Nuvalent for more than $9 billion: FT

 GSK is reportedly in talks to acquire clinical‑stage cancer biotech Nuvalent for more than $9 billion, according to the Financial Times; the deal—if true—would mark a major expansion of GSK’s oncology pipeline. Nuvalent’s market cap stands around $8–8.5 billion

https://www.globalbankingandfinance.com/gsk-talks-buy-cancer-biotech-nuvalent-9-billion-ft-reports/